Variant: rs112445441

present in Gene: KRAS present in Chromosome: 12 Position on Chromosome: 25245347 Alleles of this Variant: C/A;G;T

rs112445441 in KRAS gene and Colorectal Neoplasms PMID 20921465 2010 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

PMID 20921462 2010 Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

PMID 19114683 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

PMID 18316791 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

PMID 16361624 2005 Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.

PMID 26623049 2015 Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.

PMID 16618717 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

PMID 21398618 2011 Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

PMID 19679400 2009 Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.

PMID 21228335 2011 Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

PMID 20978259 2010 Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

PMID 23182985 2013 Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.

PMID 22734028 2012 Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

PMID 24558511 2014 KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.

PMID 22392911 2012 Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs112445441 in KRAS gene and Leukemia, Myelocytic, Acute PMID 2278970 1990 RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.

PMID 22407852 2012 RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

PMID 19075190 2009 High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

PMID 16434492 2006 Implications of NRAS mutations in AML: a study of 2502 patients.

PMID 3122217 1987 RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

rs112445441 in KRAS gene and Non-Small Cell Lung Carcinoma PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

PMID 18794081 2008 Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

PMID 15696205 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

rs112445441 in KRAS gene and Thyroid Neoplasm PMID 19255327 2009 Phase II trial of sorafenib in metastatic thyroid cancer.

PMID 23406027 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

PMID 17384584 2007 Hyperactive Ras in developmental disorders and cancer.

PMID 19773371 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

rs112445441 in KRAS gene and ovarian neoplasm PMID 21975775 2011 Epidermal growth factor receptor blockers for the treatment of ovarian cancer.

PMID 19018267 2008 KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.